ICER Draft Report Deems Four COVID Drugs Reasonably Priced

The manufacturers of four treatments aimed at easing the disease burden of mild-to-moderate COVID-19 received good news recently when the Institute for Clinical and Economic Review (ICER) determined in a draft report that their prices are “reasonably aligned with patient benefits.”

Each of the treatments — molnupiravir, Paxlovid and fluvoxamine, which are delivered orally, and the IV-administered sotrovimab — have been shown in clinical trials to greatly reduce the risk of hospitalization or death in comparison to placebo treatments, according to a draft evidence report released Feb. 3 by ICER.

© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

woman-getting-covid-19-vaccination-at-home
October 14

COVID-19 Treatment Candidates, at a Glance

READ MORE
merck-covid-19-vaccine
October 14

Merck COVID-19 Drug Could Gain Emergency Use Authorization

READ MORE
post-default-image
January 14

Prices for COVID-19 Vaccines, Drugs Could Consider Value

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today